Last reviewed · How we verify
ERGOLOID
At a glance
| Generic name | ERGOLOID |
|---|---|
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
Common side effects
Key clinical trials
- ERG/5-HTP in Fragile X Syndrome (FXS) (PHASE2)
- Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERGOLOID CI brief — competitive landscape report
- ERGOLOID updates RSS · CI watch RSS